Malaria Disease

Published Date : Oct 2023
Category : Infectious Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Pathways to Progress: Understanding the Malaria Disease Landscape

Millions of people worldwide continue to experience symptoms of malaria each year, making malaria prevention and treatment a top priority for public health initiatives. Government programs play a key role in promoting awareness, research, and development in these domains, while market participants contribute through product development and innovation.

Malaria, a mosquito-borne infectious disease caused by the Plasmodium parasite, has long been a global health concern due to its widespread prevalence and significant impact on human populations. With approximately half of the world's population at risk of contracting the disease, malaria remains a pressing public health issue that affects millions of people worldwide.

The most recent World Malaria Report, published in December 2021, estimates that there were 241 million cases of malaria worldwide in 2020, with 627,000 fatalities as a result. In comparison to 2019, this amounts to around 14 million more cases in 2020 and 69,000 more fatalities.

Certain mosquito species can transmit the deadly disease malaria to humans. It is mostly found in tropical countries. Malaria is frequently spread by female Anopheles mosquitoes biting humans. Blood transfusions and infected needles are additional ways that malaria can spread.  The five Plasmodium parasite species that cause malaria in humans include the two most lethal ones, Plasmodium falciparum and P. vivax. P. falciparum, a malaria parasite, is the deadliest.

The initial signs of malaria are sometimes hard to identify because they are mild and comparable to those of many febrile disorders. If P. falciparum malaria is not treated, it leads to severe sickness and death within 24 hours. Fever, chills, and headache are considered mild symptoms. Fatigue, confusion, convulsions, and breathing difficulties are among the severe symptoms. P. malariae, P. ovale, and P. knowlesi are the additional types of malaria that infect people.

The risk of serious illness is greatest in infants, kids under 5, pregnant women, travelers, and those with HIV or AIDS. A little more than 80% of all malaria deaths in the region were caused by children under the age of five.

Malaria is a disease that spreads between continents, primarily in sub-Saharan Africa, South Asia, and parts of Central and South America. It affects both tropical and subtropical climates. Alarming data show how widespread it is: in 2019, there were an estimated 229 million cases of malaria worldwide, which resulted in over 400,000 fatalities. P. falciparum is the most prevalent and dangerous malaria parasite on the continent of Africa.

Just over half of all malaria deaths worldwide occurred in four African nations: Nigeria (31.3%), the Democratic Republic of the Congo (12.6%), the United Republic of Tanzania (4.1%), and Niger (3.9%).

The most common malaria parasite outside of sub-Saharan Africa is P. vivax. Africa accounted for a sizable portion of the 228 million cases of malaria reported worldwide in the World Health Organization (WHO) Report 2021.

Governments across every part of the world understand how crucial it is to spread knowledge about malaria illness, particularly in terms of diagnostics and vaccinations. Government programs are crucial in promoting awareness, research, and development in these domains.

For Instance, The Bill & Melinda Gates Foundation pledged USD 24 million over three years to the Global Health Innovative Technology (GHIT) Fund in May 2023. The third five-year plan for the GHIT Fund, which runs from FY2023 to FY2027, will receive this financing. To solve issues with global health, the GHIT Fund has been actively funding the creation of new products and launching portfolio management projects.

Companies that invest in research and development include pharmaceutical firms, diagnostic device producers, and universities. Additionally, market participants are actively working to produce malaria vaccines in an effort to establish efficient preventive measures that lessen the disease's burden on a global scale.

By offering insights on the Malaria Disease market, informed choices in medical devices, treatments, and diagnostic procedures, and information on how various new technologies and innovations are affecting the disease market and fueling higher expansion, Disease Landscape Insights supports the stakeholders.

The global expansion of the malaria disease has severely impacted people's quality of life. With the support of DiseaseLandscape Insights and its services in the area of Infectious Disease. The Present Condition of the Malaria Disease Market would grow in healthcare industries in the appropriate direction and provide emerging opportunities for a variety of market leaders with the assistance of Disease Landscape Insights in the domain of Infectious Disease. Together, in this collaborative ecosystem, we promote public health, reduce the impact of the disease, and work towards the ultimate goal of eradicating Malaria.

"Advancements in Mosquito Diagnosis: From Microscopy to Molecular Screening"

Diagnostic Analysis:

Diagnosing malaria is a critical step in the management and treatment of this potentially life-threatening disease. Several diagnostic techniques are employed to detect the presence of the malaria parasite in a patient's blood. These techniques are typically categorized into two main approaches: microscopic examination and rapid diagnostic tests (RDTs).

Microscopic Examination:

One of the most popular and accurate approaches for detecting malaria is a microscopic analysis of blood smears. To check for Plasmodium parasites, a skilled laboratory professional looks at a thin blood smear beneath a microscope. Giemsa stain is frequently used to highlight the parasites and facilitate parasite identification.

This technique enables the identification of the Plasmodium species implicated and offers a quantitative evaluation of the parasite burden, both of which are critical for determining the severity of the illness.

Over 204 million microscopic malarial tests were performed globally, according to WHO estimates. This technique allows for the identification of malarial parasites including P. falciparum, P. malariae, P. ovale, and P. vivax at various stages of life. Although very accurate, this procedure calls for knowledgeable individuals and can take some time.

Laboratory Tests:

  • Rapid Diagnostic Tests (RDTs):

Rapid diagnostic tests (RDTs), particularly in regions with limited resources, have transformed malaria diagnosis. These tests are easy to use and don't need specialist lab equipment or a lot of training. RDTs function by identifying particular malaria antigens in a patient's blood, typically histidine-rich protein 2 or Plasmodium lactate dehydrogenase. A tiny amount of blood is normally added to a test strip, and the results are typically available in 15 to 30 minutes. RDTs are especially helpful for speedy diagnosis in rural locations with limited access to laboratory facilities.

  • Serological Tests:

The immune system produces antibodies in response to malaria infection, and serological tests like ELISA identify those antibodies. The prevalence of past or present infections in a population is determined by using these tests in epidemiological studies and monitoring, even though they are not typically utilized for the routine diagnosis of acute malaria cases. Serological tests, however, cannot reveal if an individual has active parasites at the present moment.

Polymerase Chain Reaction (PCR):

The very sensitive molecular technique known as polymerase chain reaction (PCR) is used to find and confirm the presence of malaria parasites in a patient's blood. For accurate species identification and quantification, PCR identifies the parasite's DNA, making it useful for research, surveillance, and epidemiological studies. However, PCR is more difficult to use in environments with limited resources since it necessitates specialized laboratory tools and qualified workers.

Overall, a variety of methods, such as microscopic examination, rapid diagnostic tests (RDTs), polymerase chain reaction (PCR), and serological assays, are used to diagnose malaria. The selection of a diagnostic technique is affected by a number of variables, including the availability of resources, the facility's location, and the precise goals of the diagnosis, such as direct patient treatment or epidemiological study. In order to ensure suitable treatment and control of malaria outbreaks, accurate and prompt diagnosis is essential.

The below table provides names of the market competitors who are transforming healthcare with advanced diagnostic breakthroughs, are listed below,

                                                                               Diagnostic Market Players

PCR Machines

Laboratory Equipment for RDTS Test

Serological Test kits and assays

Thermo Fisher Scientific

Abbott Laboratories

Bio-Rad Laboratories, Inc

Bio-Rad Laboratories

Access Bio, Inc

DiaSys Diagnostic Systems

Roche Diagnostics

Chembio Diagnostic Systems, Inc

SD Biosensor, In


SD Biosensor, Inc.


Agilent Technologies

Mologic Ltd


Bioneer Corporation

DiaSys Diagnostic Systems GmbH

Chembio Diagnostic Systems, I



PCR Machines

Laboratory Equipment for RDTS Test

Serological Test kits & Assay

LightCycler® Real-Time PCR Syste

BinaxNOW Malaria Test

Access Bio, Inc.:

DPP Malaria Assay

CFX Real-Time PCR Detection Systems

BioPlex 2200 Malaria IgG Kit

Malaria Ag P.f/Pan Cassette Test

Applied Biosystems™ QuantStudio™ Real-Time PCR Systems

Malaria Ag P.f/Pan Cassette Test

CareStart Malaria Test

QIAcube Connect and QIAgility automated PCR systems

DPP Malaria Assay

SD BIOLINE Malaria Ag P.f/Pan

AriaMx Real-Time PCR System


Cobas Malaria Test

ExiStation™ Real-Time PCR System



Mastercycler® X50 family




" Optimizing the Malaria Treatment: From Detection through Complete Recovery"

Treatment Analysis:

Certainly, there are multiple malaria treatments available including medicines, therapies, and other techniques

Antibiotic Treatments:

  • Artemisinin-Based Combination Therapies (ACTs): ACTs are the frontline treatments for uncomplicated malaria. They typically combine an artemisinin derivative with another antimalarial drug to increase effectiveness and reduce the risk of drug resistance. Common examples include Artemether-Lumefantrine (Coartem) and artesunate-amodiaquine.
  • Quinine: Quinine and its derivatives have been used for centuries to treat malaria. Although less commonly used today due to potential side effects, they are still effective against certain strains of the parasite. Quinine-based treatments include quinine sulfate and quinidine.
  • Chloroquine is an older antimalarial drug that was widely used for treating malaria caused by Plasmodium vivax and Plasmodium ovale in regions where these species are sensitive to it. However, resistance to chloroquine has emerged in many parts of the world, limiting its effectiveness.


  • Intravenous (IV) Quinine: In severe cases of malaria or when oral medications cannot be taken, IV quinine is administered in a hospital setting. It is a crucial therapy for severe malaria.
  • Blood Transfusion: Severe malaria leads to anemia and a reduction in red blood cell count. In such cases, blood transfusions are necessary to restore blood volume and oxygen-carrying capacity.
  • Artemisinin-based combination therapies (ACTs) are the first-line treatment for uncomplicated malaria caused by Plasmodium falciparum, the deadliest malaria parasite species. ACTs combine an artemisinin derivative (such as artemether or artesunate) with one or more other antimalarial drugs (like lumefantrine or mefloquine).

These combinations are highly effective and work rapidly to clear the parasites from the bloodstream. ACTs are well-tolerated and have played a crucial role in reducing malaria-related mortality.

Other Methods:

  • Chemoprevention: In regions with high malaria transmission, individuals at risk, such as pregnant women and young children, receive intermittent preventive treatment with antimalarial drugs as a preventive measure.
  • Vaccines: While no fully effective malaria vaccine exists yet, ongoing research has led to the development of partially effective vaccines, such as the RTS, S/AS01 vaccine, which is primarily used in children in malaria-endemic regions.

Since October 2021, WHO has recommended broad use of the RTS, S/AS01 malaria vaccine among children living in regions with moderate to high P. falciparum malaria transmission. It has been demonstrated that the vaccine considerably lowers the risk of childhood malaria, including malaria which can be fatal.

Vector control:

Due to its great efficacy in avoiding infection and lowering disease transmission, vector management is a crucial part of malaria control and elimination methods. The two primary treatments are ITNs (insecticide-treated nets) and IRS (indoor residual spraying).

The global effort to combat malaria is in danger due to the Anopheles mosquito's growing pesticide resistance. According to the most recent World Malaria Report, additional risks to ITNs include inadequate access, the loss of nets brought on by the strains of daily life outpacing replacement, and changing mosquito behavior, which appears to be attacking early in the evening before people go to bed and sleeping outside to avoid exposure to insecticides.

It's important to note that the choice of treatment depends on factors such as the type of malaria parasite, its resistance to drugs in a particular region, the severity of the disease, and the patient's age and overall health. Treatment should always be guided by a healthcare professional's recommendations and local health authorities' guidelines.

DiseaseLandscape Insights assists the market player in changing and growing in the malaria treatment sector and expanding globally to treat Malaria to improve patient retention, explore innovations in the treatment area, and achieve new business heights.

DLI enables market participants to maintain a competitive edge through our thorough analysis of treatment options, service contributions, product inventories, and market competitiveness. We provide important help in conducting and analyzing clinical studies for the creation of innovative medications as a dedicated collaborator to the pharmaceutical industry.

The market for malaria disease is extremely diverse and needs a major driver with a global presence.

The table below provides details about a drug class, drug names, recommended dosages, and side effects of each drug -

                                                                                       Treatment Market Players


Combination Therapies




GlaxoSmithKline (GSK)

AR Scientific, Inc

Medicef Pharma



Ipca Laboratories






Guilin Pharmaceutical






GlaxoSmithKline (GSK)



The below table shows the key market player who are redefining the treatment industry and their product names-



Combination Therapies




RTS,S/AS01 (trade name: Mosquirix)



PfSPZ Vaccine





Ajanta Artemether Lumefantrine





Artesunate + Amodiaquine




"Exploring the Landscape: Key Market Trends in Malaria Infection Management"

Market Trend Analysis:

In recent years, the malaria industry has seen considerable alterations and advances, owing to a global effort to battle this fatal illness. The significant rise in financing for malaria prevention, research, and control is one noticeable trend. Governments, international organizations, and charitable foundations have continued to devote significant resources to addressing the effects of malaria, leading to a more competitive market environment.

For example, as of June 2023, the Global Fund offers 65% of all international funding for malaria programs and has committed in excess of US$17.9 billion to malaria control programs. These funds are making a difference.

Antimalarial treatment innovations have been a key market trend. Researchers and pharmaceutical corporations have been working hard to develop new antimalarial treatments. These efforts have resulted in next-generation drug combinations and formulations that are more effective in combating drug-resistant malaria parasite strains. The focus on medication development seeks to improve therapy choices for persons suffering from the condition.

Rapid diagnostic tests (RDTs) have become essential in the diagnosis of malaria. One important tendency is to make RDTs more accessible and affordable. These tests are becoming more widely available to healthcare practitioners and populations in malaria-endemic areas, allowing for faster and more accurate diagnosis, which is critical for prompt treatment and limiting disease transmission. 

According to WHO data, approximately 312 million RDTs were administered globally in 2016. According to national malaria control program reports and manufacturer sales statistics, 225 million P. falciparum tests were provided throughout Africa, with the remainder being a combination of P. ovale, P. falciparum, P. malaria, and P. vivax tests.

The worldwide malaria eradication targets are gaining traction. Several governments and regions have set goals to eradicate malaria within certain geographic areas. This trend represents a change away from just managing the illness and towards aggressively pursuing its eradication, a critical step forward in the worldwide fight against malaria.

According to the report, the government of Malawi began the 'Zero Malaria Starts with Me' campaign in June 2021 to abolish malaria by 2030, which is the leading cause of mortality in Malawi and accounts for 15% of hospital admissions in Malawi. Malaria has undergone dynamic changes and breakthroughs as a result of scientific discoveries, public health goals, and new difficulties.

"Innovative Companies in Malaria Infection Control: A Competitive Evaluation"

Competitive Analysis:

In the malaria market, several key players have a significant impact on the dynamics of the industry. Pharmaceutical giants like Novartis, GlaxoSmithKline (GSK), and Sanofi have long been engaged in research, development, and distribution of antimalarial drugs. These companies compete not only in terms of the effectiveness of their products but also in ensuring affordability and accessibility in regions where malaria is endemic.

Additionally, research organizations, government agencies, non-profit organizations, and international bodies, including the World Health Organization (WHO) and the Bill and Melinda Gates Foundation, play pivotal roles in funding and coordinating global malaria control efforts.

  • In 2021, Zydus Cadila and Medicines for Malaria Venture announced their proposal to develop the antimalarial medication ZY19489, which got U.S. FDA approval. According to the manufacturer, ZY19489's Phase I trial revealed that it has a lengthy half-life and the potential to treat malaria with a single dose. Strong antimalarial activity has been observed following oral administration of ZY19489 in a different malaria challenge study.
  • Vaccine development has become a highly competitive focus in the malaria market. Companies like GSK, in partnership with organizations like PATH Malaria Vaccine Initiative, have been pioneering the development of malaria vaccines.
  • In addition, the Gates Foundation-funded Gavi vaccination project will debut the Mosquirix vaccine, created by GlaxoSmithKline (GSK), in three African nations, Ghana, Kenya, and Malawi, in July 2022. This vaccine is believed to be the first anti-malarial vaccine ever developed.

Global partnerships and collaborations play a substantial role in the malaria market. For instance, on March 8, 2023, FFF Enterprises Inc., a provider of critical-care biopharmaceuticals, plasma products, and vaccines, declared that it had joined forces with Amivas, Inc., a U.S. joint venture specializing in the development, manufacture, and commercialization of therapeutic products for the treatment of infectious diseases, to stock Artesunate for Injection, the life-saving antimalarial medication for severe malaria.

Lastly, emerging markets, particularly in Africa, are of keen interest to companies and organizations in the malaria market. These regions bear the highest malaria burden, making them both a challenge and an opportunity. Tailoring products and strategies to meet the specific needs and challenges of these markets is a competitive advantage that influences market dynamics.

By providing in-depth knowledge about all the current market participants, their innovations, tactics, and collaborations, DiseaseLandscape Insights helps the industry participants choose the best market to grow exponentially.

"Compliance and Progress: A Regulatory Framework Assessment for Malaria Eradication"

Regulatory Framework Analysis:

DiseaseLandscape Insights has greatly reduced the regulatory framework for significant players in the malaria disease landscape. DLI helps the stakeholders understand foreign governments' import/export laws, regulatory systems, and monitoring procedures. Key parties effectively prevent, manage, and respond to malaria epidemics by considering the well-being of the impacted community.

Setting international standards and guidelines for malaria control and prevention is a major responsibility of the World Health Organization (WHO). The WHO's Global Malaria Program assists member states in developing and implementing national malaria control programs by offering technical advice and support. The "Global Technical Strategy for Malaria," which specifies the objectives, benchmarks, and suggested solutions for malaria control globally, is a component of the framework. The WHO also runs the "Prequalification of Medicines Programme," which assesses the effectiveness, safety, and quality of antimalarial medications to make sure they adhere to international standards.

The regulatory framework also extends to the pharmaceutical industry, where stringent rules govern the development, testing, and approval of antimalarial drugs. Regulatory authorities in countries with a significant malaria burden collaborate with international organizations to evaluate and approve new drugs and vaccines.

  • For Instance, Lumen Bioscience, Inc., a clinical-stage biotechnology company, announced the availability of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria in October 2022. The vaccine is designed to treat and prevent highly prevalent diseases.
  • For instance, in March 2022, Medicines for Malaria Venture (MMV), a company that co-developed tafenoquine with GlaxoSmithKline (GSK) to treat a specific type of malaria, received approval from the Australian government. The drug is coupled with chloroquine, a popular anti-malarial drug.

DLI provides empirical data on regulatory compliance, risk monitoring, and risk assessment. By examining the DiseaseLandscape Insights services, organizations, and market players, respond to malaria symptoms, and ensure the safety of patients.

Clinical Trial Assessment:

The government's increased focus on comparing the efficacy of studies draws attention to the critical role that clinical trials play in the practice of evidence-based medicine and health care reform. One of the key objectives of healthcare reform is attained when market players thoroughly evaluate medical therapy using clinical data.

The names of the ongoing clinical trial studies and the stages they are in are shown in the table below.

Phase 1

Phase 2

Phase 3

Phase 4

A Randomised, Controlled, Double-blind, Parallel Group, Single Center Phase Ib Trial to Assess Safety, Reactogenicity, Immunogenicity and Parasite Growth Rates After Controlled Human Malaria Infection of a Candidate Dual-stage Malaria Vaccine, SumayaVac-1 (MSP-1 With GLA-SE as Adjuvant) in Healthy Malaria Exposed Adults of African Origin Aged 18-45 Years

A Randomized, Open Label, Single Centre, Phase 2 Trial of the Malaria Vaccine, R21/Matrix-M, to Assess Safety and Immunogenicity of the Vaccine in Thai Adults

Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda

A Hybrid Effectiveness-implementation Study to Assess the Effectiveness and Chemoprevention Efficacy of Implementing Seasonal Malaria Chemoprevention in Five Districts in Karamoja Region, Uganda

Phase 1 Dose Escalation Study of The Plasmodium Vivax Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-Blocking Activity in Healthy Malaria-Naive Adults

Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults

Treating Brain Swelling in Pediatric Cerebral Malaria

Ivermectin-artemisinin Combination Therapy for Eradication of Malaria

A Phase Ib Multi-Stage Plasmodium Falciparum Malaria Vaccine Study to Assess the Safety and Immunogenicity of the Blood-stage Vaccine Candidate RH5.2 Virus-like Particle (VLP) in Matrix-M and the Pre-erythrocytic Stage Vaccine Candidate R21 in Matrix-M, Both Alone and in Combination, in Adults and Infants in the Gambia

Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents with Acute Uncomplicated Plasmodium Falciparum Malaria

Enhancing Immunity to Malaria in Young Children with Effective Chemoprevention

Evaluation of the Efficacy of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in Children with Uncomplicated Clinical Malaria in Rural Rwanda

A Phase 1, Dose Escalation, Double-Blind, Placebo-Controlled Clinical Trial with Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, MAM01, in Healthy, Malaria-Naive Adults

Phase IIB Study to Evaluate Primaquine Safety and Tolerability for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children < 15 Years old (CHILDPRIM)

Evaluating the Renoprotective Effect of Paracetamol in Paediatric Severe Malaria: a Randomised Controlled Trial

Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa



For malaria-specific diagnostics and treatments, there are many market scenarios pertaining to various nations and areas. Governments have made a variety of investments and established institutes in the field of malaria detection and treatment due to the impact of malaria diseases and the challenges associated with the economic feasibility of treating malaria.

DiseaseLandscape Insights (DLI) assists in locating the target market, directing marketing strategies, and informing market players of new trends. By conducting thorough market research, DiseaseLandscape Insights assists manufacturers in creating and implementing efficient medications to stop and control Malaria outbreaks.

The strategic knowledge needed to launch and run a healthcare firm is provided by DLI's thorough market analyses, which also help industry participants make wise and profitable business choices.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape